1

Aceto Corporation

#9151

Rank

$74.98M

Marketcap

US United States

Country

Aceto Corporation
Leadership team

Dr. Aya Jakobovits Ph.D. (Founder & Independent Director)

Mr. Brian Nicholas Harvey (Chief Financial Officer)

Number of Employees
50 - 100
Headquarters
New York, New York, United States
Established
1947
Company Registration
SEC CIK number: 0001720580
Revenue
20M - 100M
Traded as
ACET
Overview
Location

Summary

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

Key Team

Dr. Francesco Galimi M.D., Ph.D. (Chief Medical Officer & Sr. VP)

Dr. Donald Healey (Chief Technology Officer)

Dr. Blake Aftab Ph.D. (Sr. VP & Chief Scientific Officer)

Dr. Nancy L. Boman M.D., Ph.D. (Sr. VP & Chief Regulatory Officer)

References
Aceto Corporation
Leadership team

Dr. Aya Jakobovits Ph.D. (Founder & Independent Director)

Mr. Brian Nicholas Harvey (Chief Financial Officer)

Number of Employees
50 - 100
Headquarters
New York, New York, United States
Established
1947
Company Registration
SEC CIK number: 0001720580
Revenue
20M - 100M
Traded as
ACET